Related Experiment Video
Updated: Jun 7, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Intraperitoneal chemotherapy: why the fuzz?
1Division of Gynecologic Oncology, McGill University and Segal Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada. walter.gotlieb@mcgill.ca
Summary
Intraperitoneal (IP) chemotherapy significantly reduces the risk of death by 19-25% compared to intravenous chemotherapy. This survival benefit for IP chemotherapy is observed despite varying treatment protocols.
Area of Science:
- Oncology
- Cancer Treatment
- Clinical Trials
Background:
- Intraperitoneal (IP) chemotherapy is a method of administering chemotherapy directly into the peritoneal cavity.
- Evaluating the efficacy of IP chemotherapy compared to traditional intravenous administration is crucial for optimizing cancer treatment strategies.
Purpose of the Study:
- To critically evaluate the benefits of intraperitoneal (IP) chemotherapy.
- To review the existing literature supporting the use of IP chemotherapy.
Main Methods:
- A critical review of scientific literature.
- Analysis of data from the largest randomized phase III trials.
Main Results:
- Three major Gynecologic Oncology Group (GOG) randomized phase III trials were analyzed.
- IP chemotherapy demonstrated a 19% to 25% reduction in the risk of death compared to intravenous chemotherapy.
- These significant survival benefits were observed over a 10-year study period.
Conclusions:
- IP chemotherapy offers a significant survival advantage for patients.
- The precise mechanism, whether local drug effect or reservoir effect, requires further investigation.
- Observed improvements in overall survival are undeniable and support the use of IP chemotherapy.
